Inventor · disambiguated record
Abbot F. Clark
Also filed as: CLARK ABBOT F · CLARK ABBOT FREDERICK
58 granted patents·68 pending applications·1,635 citations·filing 1988–2019
99Inventor score
Top patents by PatentIndex Score
126 records- 0196US5371078AAngiostatic steroids and methods and compositions for controlling ocular hypertensionALCON LAB INC·Filed 1992·Granted Dec 6, 1994·104 cites·10 claims
- 0295US7947660B2RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucomaALCON INC·Filed 2006·Granted May 24, 2011·31 cites·18 claims
- 0395US4876250AMethods for controlling ocular hypertension with angiostatic steroidsALCON LAB INC·Filed 1988·Granted Oct 24, 1989·97 cites·6 claims
- 0494US8173617B2RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucomaCLARK ABBOT F·Filed 2011·Granted May 8, 2012·31 cites·17 claims
- 0594US6011023AAngiostatic steroidsALCON LAB INC·Filed 1997·Granted Jan 4, 2000·111 cites·14 claims
- 0694US5679666APrevention and treatment of ocular neovascularization by treatment with angiostatic steroidsALCON LAB INC·Filed 1994·Granted Oct 21, 1997·77 cites·18 claims
- 0793US7973019B1Transferrin/transferrin receptor-mediated siRNA deliveryALCON RES LTD·Filed 2008·Granted Jul 5, 2011·16 cites·13 claims
- 0893US7592324B2RNAi-mediated inhibition of ocular targetsALCON INC·Filed 2006·Granted Sep 22, 2009·26 cites·37 claims
- 0993US6297228B1Use of angiostatic steroids in photodynamic therapyALCON MFG LTD·Filed 1998·Granted Oct 2, 2001·108 cites·5 claims
- 1092US5770592APrevention and treatment of ocular neovascularization using angiostatic steroidsALCON LAB INC·Filed 1997·Granted Jun 23, 1998·91 cites·5 claims
- 1191US6413245B1Sub-tenon drug deliveryALCON UNIVERSAL LTD·Filed 2000·Granted Jul 2, 2002·306 cites·36 claims
- 1291US6177427B1Treatment of glaucoma and ocular hypertensionALCON LAB INC·Filed 1999·Granted Jan 23, 2001·50 cites·3 claims
- 1389US8399653B2Transferrin/transferrin receptor-mediated siRNA deliveryCHATTERTON JON E·Filed 2011·Granted Mar 19, 2013·8 cites·6 claims
- 1489US5990099AAngiostatic agents and methods and compositions for controlling ocular hypertensionALCON LAB INC·Filed 1997·Granted Nov 23, 1999·87 cites·3 claims
- 1589US5521168AEstrogen metabolites for lowering intraocular pressureALCON LAB INC·Filed 1994·Granted May 28, 1996·94 cites·11 claims
- 1687US5464866ASubstituted hydrindanes for the treatment of angiogenesis-dependent diseasesALCON LAB INC·Filed 1994·Granted Nov 7, 1995·30 cites·4 claims
- 1787US5407926AOphthalmic compositionALCON LAB INC·Filed 1992·Granted Apr 18, 1995·49 cites·10 claims
- 1885US6444676B1Use of PARP inhibitors in the treatment of glaucomaFiled 2000·Granted Sep 3, 2002·16 cites·4 claims
- 1984US7744873B2Method for treating glaucoma comprising administering to a patient in need thereof a composition comprising an antibody against gremlinALCON INC·Filed 2008·Granted Jun 29, 2010·5 cites·1 claims
- 2083US7662389B2Use of serum amyloid A gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agentsALCON INC·Filed 2006·Granted Feb 16, 2010·5 cites·2 claims
- 2182US7598288B2Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucomaALCON INC·Filed 2002·Granted Oct 6, 2009·17 cites·19 claims
- 2281US4945089AUse of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroidsALCON LAB INC·Filed 1989·Granted Jul 31, 1990·59 cites·10 claims
- 2379US5698545AAngiostatic steroids and methods and compositions for controlling ocular hypertensionALCON LAB INC·Filed 1996·Granted Dec 16, 1997·29 cites·3 claims
- 2478US9476047B2RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditionsARROWHEAD RES CORP·Filed 2015·Granted Oct 25, 2016·1 cites·13 claims
- 2578US7807363B2Superoxide dismutase-2 expression for glaucoma diagnosisALCON RES LTD·Filed 2007·Granted Oct 5, 2010·5 cites·8 claims
- 2678US7351407B2Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathiesALCON INC·Filed 2003·Granted Apr 1, 2008·13 cites·11 claims
- 2775US9562230B2Transferrin/transferrin receptor-mediated siRNA deliveryARROWHEAD RES CORP·Filed 2015·Granted Feb 7, 2017·1 cites·11 claims
- 2870US9173896B2RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditionsCHATTERTON JON E·Filed 2009·Granted Nov 3, 2015·0 cites·14 claims
- 2970US7405192B2Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucomaALCON INC·Filed 2002·Granted Jul 29, 2008·3 cites·8 claims
- 3070US7005446B1Use of AP-1 activators to treat glaucoma and ocular hypertensionALCON MFG LTD·Filed 2000·Granted Feb 28, 2006·2 cites·3 claims
- 3170US6172054B1Combination therapy for lowering and controlling intraocular pressureALCON LAB INC·Filed 1995·Granted Jan 9, 2001·37 cites·16 claims
- 3270US2009226425A1Diagnostics and Therapeutics For GlaucomaALCON INC·Filed 2009·Application pending·0 cites
- 3369US7384926B2Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucomaALCON INC·Filed 2007·Granted Jun 10, 2008·0 cites·3 claims
- 3468US7357931B2Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agentsALCON INC·Filed 2004·Granted Apr 15, 2008·5 cites·1 claims
- 3568US2009275641A1RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular DisordersALCON RES LTD·Filed 2009·Application pending·0 cites
- 3667US5686621ASubstituted hydrindanes for the treatment of angiogenesis-dependent diseasesALCON LAB INC·Filed 1995·Granted Nov 11, 1997·27 cites·4 claims
- 3766US9139834B2RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesisARROWHEAD RES CORP·Filed 2014·Granted Sep 22, 2015·0 cites·17 claims
- 3866US2007142376A1Control of intraocular pressure using alk5 modulation agentsALCON INC·Filed 2006·Application pending·0 cites
- 3966US2009036397A1RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMAALCON RES LTD·Filed 2008·Application pending·0 cites
- 4066US2009036396A1RNAi-RELATED INHIBITION OF TNFalpha SIGNALING PATHWAY FOR TREATMENT OF OCULAR ANGIOGENESISALCON RES LTD·Filed 2008·Application pending·0 cites
- 4165US9752147B2RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditionsARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Sep 5, 2017·0 cites·21 claims
- 4264US10138483B2Transferrin/transferrin receptor-mediated siRNA deliveryARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Nov 27, 2018·0 cites·7 claims
- 4364US9114152B2Transferrin/transferrin receptor-mediated siRNA deliveryARROWHEAD RES CORP·Filed 2013·Granted Aug 25, 2015·0 cites·7 claims
- 4464US6090798ATreatment of GLC1A glaucoma with glucocorticoid antagonistsALCON LAB INC·Filed 1997·Granted Jul 18, 2000·23 cites·3 claims
- 4564US2009326044A1RNAi-Mediated Inhibition of Ocular TargetsALCON RES LTD·Filed 2009·Application pending·0 cites
- 4664US2008057072A1Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disordersALCON MFG LTD·Filed 2007·Application pending·0 cites
- 4763US2014357692A1RNAi Inhibition of Serum Amyloid A For Treatment of GlaucomaNOVARTIS AG·Filed 2014·Application pending·0 cites
- 4862US6051573ATreatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonistsALCON LAB INC·Filed 1997·Granted Apr 18, 2000·16 cites·4 claims
- 4961US2013123337A1RNAi Inhibition of Serum Amyloid A For Treatment of GlaucomaNOVARTIS AG·Filed 2012·Application pending·0 cites
- 5061US2010063052A1Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agentsALCON INC·Filed 2009·Application pending·0 cites
Showing the top 50 of 126 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →